Camzyos is an oral, selective allosteric and reversible inhibitor of cardiac myosin. It was approved in April 2022 for the treatment of adults with symptomatic New York Heart Association (NYHA) class ...

1,3 Additionally, CAMZYOS is no longer contraindicated with moderate CYP2C19 inhibitors and strong CYP3A4 inhibitors, which were adjusted to drug interactions. This provides physicians with ...

Genedrive plc has been awarded additional funding under the DEVOTE programme, a collaboration aimed at integrating genomic technology into clinical practice. The company received approximately £1.2 ...

The company achieved its first UK commercial sales of the Genedrive® CYP2C19-ID Kit and secured a positive assessment from the Scottish Health Technologies Group, leading to government investment ...